In 2016, we reported that a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) induces lasting normoglycemia in multiple rodent models of T2D [3], and in 2019, that FGF1 microinjection directly into the arcuate nucleus-median eminence recapitulates this sustained anti-diabetic effect [4]. The gene discussed is FGF1; the disease is type 2 diabetes mellitus.